Mainz Biomed Analyst Ratings
Mainz Biomed Analyst Ratings
While ratings are subjective and will change, the latest Mainz Biomed (MYNZ) rating was a maintained with a price target of $7.00 to $9.00. The current price Mainz Biomed (MYNZ) is trading at is $3.10, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/22/2023 | 190.32% | HC Wainwright & Co. | $7 → $9 | Maintains | Buy |
| 09/14/2023 | 190.32% | Cantor Fitzgerald | → $9 | Reiterates | Overweight → Overweight |
| 08/22/2023 | 190.32% | Cantor Fitzgerald | → $9 | Reiterates | Overweight → Overweight |
| 08/18/2023 | 125.81% | HC Wainwright & Co. | $10 → $7 | Reiterates | Buy → Buy |
| 06/01/2023 | 222.58% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 05/18/2023 | 287.1% | Cantor Fitzgerald | $15 → $12 | Maintains | Overweight |
| 04/27/2023 | 222.58% | HC Wainwright & Co. | $25 → $10 | Maintains | Buy |
| 03/30/2023 | 706.45% | HC Wainwright & Co. | → $25 | Reiterates | → Buy |
| 02/16/2023 | 706.45% | HC Wainwright & Co. | → $25 | Reiterates | → Buy |
| 02/10/2023 | 254.84% | JonesTrading | → $11 | Initiates Coverage On | → Buy |
| 10/25/2022 | 383.87% | Cantor Fitzgerald | → $15 | Initiates Coverage On | → Overweight |
| 06/21/2022 | 706.45% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/22/2023 | 190.32% | HC Wainwright公司 | $7→$9 | 維護 | 買 |
| 09/14/2023 | 190.32% | 康託·菲茨傑拉德 | →$9 | 重申 | 超重→超重 |
| 2023年08月22日 | 190.32% | 康託·菲茨傑拉德 | →$9 | 重申 | 超重→超重 |
| 2023年08月18日 | 125.81% | HC Wainwright公司 | $10→$7 | 重申 | 購買→購買 |
| 06/01/2023 | 222.58% | HC Wainwright公司 | →$10 | 重申 | →購買 |
| 2023年05月18日 | 287.1% | 康託·菲茨傑拉德 | $15→$12 | 維護 | 超重 |
| 04/27/2023 | 222.58% | HC Wainwright公司 | $25→$10 | 維護 | 買 |
| 03/30/2023 | 706.45% | HC Wainwright公司 | →$25 | 重申 | →購買 |
| 02/16/2023 | 706.45% | HC Wainwright公司 | →$25 | 重申 | →購買 |
| 02/10/2023 | 254.84% | Jones Trading | →$11 | 開始承保 | →購買 |
| 2022年10月25日 | 383.87% | 康託·菲茨傑拉德 | →$15 | 開始承保 | →超重 |
| 2022年06月21日 | 706.45% | HC Wainwright公司 | →$25 | 開始承保 | →購買 |
What is the target price for Mainz Biomed (MYNZ)?
美因茨生物科技公司(MYNZ)的目標價是多少？
The latest price target for Mainz Biomed (NASDAQ: MYNZ) was reported by HC Wainwright & Co. on September 22, 2023. The analyst firm set a price target for $9.00 expecting MYNZ to rise to within 12 months (a possible 190.32% upside). 11 analyst firms have reported ratings in the last year.
美因茨生物製藥(納斯達克：MYNZ)的最新目標價是由HC Wainwright&Co.於2023年9月22日報道的。這家分析公司將目標價定為9美元，預計紐西蘭元將在12個月內上漲(可能上漲190.32%)。過去一年，有11家分析公司公佈了評級。
What is the most recent analyst rating for Mainz Biomed (MYNZ)?
美因茨生物科技公司(MYNZ)的最新分析師評級是多少？
The latest analyst rating for Mainz Biomed (NASDAQ: MYNZ) was provided by HC Wainwright & Co., and Mainz Biomed maintained their buy rating.
美因茨生物科技(納斯達克：MYNZ)的最新分析師評級由HC Wainwright&Co.提供，美因茨生物科技維持買入評級。
When is the next analyst rating going to be posted or updated for Mainz Biomed (MYNZ)?
美因茨生物科技公司(MYNZ)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mainz Biomed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mainz Biomed was filed on September 22, 2023 so you should expect the next rating to be made available sometime around September 22, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公開財務報表，與美因茨生物美孚的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。美因茨·比默德的上一次評級是在2023年9月22日提交的，所以你應該預計下一次評級將在2024年9月22日左右的某個時候公佈。
Is the Analyst Rating Mainz Biomed (MYNZ) correct?
分析師對美因茨-比默德(MYNZ)的評級正確嗎？
While ratings are subjective and will change, the latest Mainz Biomed (MYNZ) rating was a maintained with a price target of $7.00 to $9.00. The current price Mainz Biomed (MYNZ) is trading at is $3.10, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但美因茨生物科技公司(MYNZ)的最新評級維持不變，目標價在7.00美元至9.00美元之間。美因茨-比奧梅德目前的股價為3.10美元，超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。
